The aim of the study was to examine data privacy which has become a subject of debate with the COVID-19 pandemic. While evaluating data privacy, it is considered that there is a balance between data privacy and public health in a pandemic crisis, where latter outweighs the former. Therefore, mostly the period following the pandemic was focused and which significant issues to be taken into consideration in terms of eliminating the possible negative impacts of data policies implemented today were discussed in the study. Firstly, mobile applications (such as TraceTogether and PEPP-PT) or technological infrastructures developed to track patients and provide their filings in South Korea, Taiwan, China, Europe and Singapore were explained. Increased concerns about data privacy have been expressed with such approaches. Four main matters were determined to be considered with regard to the technological applications being used as a part of COVID19 response efforts. These are: 1) Complying with regulations and international health guidelines, 2) Having transparent data collection and processing conditions, 3) Using anonymized mobile geodata, and 4) Conducting data quality and security controls. It is believed that paying attention to these matters will be beneficial after the pandemic or while developing new applications. In addition, together with the consideration of these issues and preparation of the necessary infrastructure, it has been seen that telemedicine applications can be an important power in the fight against COVID-19. It is emphasized that it can make an important contribution in controlling outbreaks and preventing unnecessary use of health services.
Keywords: COVID-19; data privacy; mobile applications; telemedicine
Bu çalışmada, COVID-19 ile birlikte tartışma konusu hâline gelen veri gizliliği konusu incelenmiştir. Veri gizliliği ile ilgili değerlendirmeler yapılırken, bir pandemi krizinde veri gizliliği ve halk sağlığı arasında bir denge olduğu, bu dengede halk sağlığı kısmının ağır bastığı yaklaşımı dikkate alınmıştır. Bu sebeple yapılan bu çalışmada, daha çok salgın sonrası süreç düşünülmüş, günümüzde uygulanan bu veri politikaları ile birlikte oluşabilecek olumsuz etkileri azaltmak için hangi önemli noktaların dikkate alınması gerektiği değerlendirilmiştir. İlk olarak Güney Kore, Tayvan, Çin, Avrupa ve Singapur'da hastaları takip etmek ve filyasyonu sağlamak için geliştirilen mobil uygulamalar (TraceTogether ve PEPP-PT gibi) veya oluşturulan teknolojik altyapılar açıklanmıştır. Bu gibi yaklaşımlar ile birlikte veri gizliliği konusunda artan endişeler ifade edilmiştir. COVID-19 ile mücadelede kullanılan teknolojik uygulamalarda 4 temel hususa dikkat edilmesi gerektiği belirlenmiştir. Bunlar: 1) Düzenleyici uygulamalara ve uluslararası sağlık yönergelerine uyulması, 2) Veri toplama ve işleme koşulları açık olması, 3) Anonimleştirilmiş mobil konumlandırma verilerinin kullanılması, 4) Veri kalitesi ve güvenlik kontrollerinin yapılmasıdır. Salgın sonrası süreçte veya geliştirilecek yeni uygulamalarda bu hususların dikkate alınmasının fayda sağlayacağı düşünülmektedir. Ayrıca bu hususların dikkate alınması ve gerekli altyapının hazırlanması ile birlikte, teletıp uygulamalarının COVID-19 ile mücadelede önemli bir güç olabileceği görülmüştür. Salgınların kontrol edilmesi ve gereksiz sağlık hizmetleri kullanımının engellenmesi noktasında önemli bir katkı sağlayabileceğine vurgu yapılmıştır
Anahtar Kelimeler: COVID-19; veri gizliliği; mobil uygulamalar; teletıp
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. Erratum in: Lancet Respir Med. 2020. [Crossref] [PubMed] [PMC]
- Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-51. [PubMed]
- Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-15. Erratum in: Lancet. 2020;395(10229):1038. Erratum in: Lancet. 2020;395(10229):1038. [Crossref] [PubMed] [PMC]
- Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ. 2020;368:m1182. [Crossref] [PubMed]
- Kandel N, Chungong S, Omaar A, Xing J. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. Lancet. 2020;395(10229):1047-53. [Crossref] [PubMed] [PMC]
- Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing. JAMA. 2020;323(14):1341-2. [Crossref] [PubMed]
- Cho H, Ippolito D, Yu YW. Contact tracing mobile apps for COVID-19: Privacy considerations and related trade-offs. arXiv. 2020;1-12. [Link]
- Abeler J, Bäcker M, Buermeyer U, Zillessen H. COVID-19 contact tracing and data protection can go together. JMIR Mhealth Uhealth. 2020;8(4):e19359. [Crossref] [PubMed] [PMC]
- Park S, Choi GJ, Ko H. Information technology-based tracing strategy in response to COVID-19 in South Korea-privacy controversies. JAMA. 2020;323(21):2129-30. [Crossref] [PubMed]
- Barbieri C, Darnis JP. Technology: An exit strategy for COVID-19? IAI Commentaries. 2020:1-6. [Link]
- Ienca M, Vayena E. On the responsible use of digital data to tackle the COVID-19 pandemic. Nat Med. 2020;26(4):463-4. [Crossref] [PubMed] [PMC]
- Oliver N, Letouzé E, Sterly H, Delataille S, De Nadai M, Lepri B, et al. Mobile phone data and COVID-19: Missing an opportunity? arXiv. 2020. [Link]
- Shachar C. Protecting privacy in digital contact tracing for COVID-19: Avoiding a regulatory patchwork. Health Affairs. 2020:1-3. [Link]
- Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: a call to action. JMIR Public Health Surveill. 2020;6(2):e18810. [Crossref] [PubMed] [PMC]
- Calton B, Abedini N, Fratkin M. Telemedicine in the time of coronavirus. J Pain Symptom Manage. 2020;60(1):e12-4. [Crossref] [PubMed] [PMC]
- Mann DM, Chen J, Chunara R, Testa PA, Nov O. COVID-19 transforms health care through telemedicine: Evidence from the field. J Am Med Inform Assoc. 2020;27(7):1132-5. [Crossref] [PubMed] [PMC]
- Leite H, Hodgkinson IR, Gruber T. New development: 'Healing at a distance' -telemedicine and COVID-19. Public Money & Management. 2020;40(6):483-5. [Crossref]
- Naudé W. Artificial intelligence against COVID-19: an early review. Discussion Paper Series. IZA DP No. 13110. [Link]
- Allam Z, Jones DS. On the coronavirus (COVID-19) outbreak and the smart city network: universal data sharing standards coupled with Artificial Intelligence (AI) to benefit urban health monitoring and management. Healthcare (Basel). 2020;8(1):46. [Crossref] [PubMed] [PMC]
- Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-81. [Crossref] [PubMed]
- Rockwell KL, Gilroy AS. Incorporating telemedicine as part of COVID-19 outbreak response systems. Am J Manag Care. 2020;26(4):147-8. [Crossref] [PubMed]
- Zhou X, Snoswell CL, Harding LE, Bambling M, Edirippulige S, Bai X, et al. The role of telehealth in reducing the mental health burden from COVID-19. Telemed J E Health. 2020;26(4):377-9. [Crossref] [PubMed]
.: Process List